Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Daré Bioscience published Phase 1 data for its topical Sildenafil Cream, 3.6%, showing topical sildenafil produced 2.55%-3.20% relative bioavailability versus a 50 mg oral dose and substantially lower systemic exposure. At the 71 mg topical dose, peak plasma concentration was approximately 187-fold lower than oral sildenafil, while AUClast and AUCinf were about 33-fold and 34-fold lower, respectively. In the 62-person study, all 14 treatment-emergent adverse events were mild, with no serious events, deaths, or treatment discontinuations; the study did not assess efficacy. The peer-reviewed data strengthen the scientific rationale for continued development in female sexual arousal disorder, but remain early-stage and do not establish clinical efficacy in women.

Analysis

The publication modestly reduces formulation-science uncertainty but does not de-risk the investable question: whether localized exposure translates into a clinically meaningful, commercially differentiated benefit in women. A male single-dose PK study has little read-through to female efficacy, dosing behavior, payer acceptance, or repeat-use tolerability; absent those data, any near-term DARE strength is likely retail-flow driven rather than a durable probability-of-success re-rating.

The relevant valuation bottleneck is financing and commercialization execution, not sildenafil’s known pharmacology. A compounded-product route may shorten time to revenue, but it substitutes FDA-approval risk with outsourcing-facility, state-licensure, quality-control and potential FDA enforcement risk; this structure also limits pricing power and creates weak barriers to formulation-adjacent competition. The key 1-3 month catalyst is evidence of actual launch readiness—named fulfillment partner, state coverage, prescription throughput and gross-margin disclosure—rather than additional peer-reviewed PK commentary.

Contrarian view: low systemic exposure can be commercially double-edged. It supports a local-safety narrative, but may prompt clinicians and investors to question whether sufficient tissue exposure and efficacy are achieved, particularly since systemic exposure is not the therapeutic endpoint. Over 6-18 months, a credible efficacy signal plus measurable direct-to-consumer conversion could justify a platform re-rating; without it, cash burn and repeated capital raises should dominate the equity’s return profile.

Key Decisions for Investors

• No new directional position on this release; treat any volume-led upside as a liquidity event until women-specific efficacy, launch timing and cash runway are independently updated.
• For existing DARE exposure, maintain a small catalyst sleeve only and reduce into a 25-40% post-release spike unless accompanied by disclosed prescription/fulfillment economics; micro-cap financing risk can overwhelm scientific-news gains within weeks.
• Set a 1-3 month diligence alert for a 503B partner, state dispensing coverage, unit pricing, gross margin and monthly prescription metrics. Initiate only if management can demonstrate early repeat demand without a near-term dilutive financing need.
• Thesis is falsified positively by reproducible female efficacy with tolerability and a funded commercialization runway; it is falsified negatively by FDA/503B policy restrictions, launch slippage, or a financing that materially expands shares outstanding.